MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Retained Earnings 2011-2026 | OPK
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.07 B | -2.01 B | -1.82 B | -1.51 B | -1.48 B | -1.51 B | -1.2 B | -1.01 B | -730 M | -705 M | -675 M | -503 M | -389 M | -360 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -360 M | -2.07 B | -1.14 B |
Quarterly Retained Earnings OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.28 B | -2.13 B | -2.08 B | -2.1 B | -2.09 B | -1.95 B | -1.86 B | -1.84 B | -1.82 B | -1.74 B | - | -1.55 B | -1.51 B | -1.44 B | -1.47 B | -1.45 B | -1.48 B | -1.48 B | -1.48 B | -1.48 B | -1.51 B | -1.51 B | -1.51 B | -1.51 B | -1.2 B | -1.2 B | -1.2 B | -1.2 B | -1.05 B | -1.04 B | -1.04 B | -1.04 B | -775 M | -730 M | -730 M | -730 M | -705 M | -705 M | -705 M | -705 M | -675 M | -675 M | -675 M | -675 M | -503 M | -503 M | -503 M | -503 M | -389 M | -389 M | -389 M | -389 M | -360 M | -360 M | -360 M | -360 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -360 M | -2.28 B | -1.12 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
348 M | $ 117.5 | 2.1 % | $ 35.7 B |  USA |
 |
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
-544 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
-735 M | $ 16.83 | 4.86 % | $ 897 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
-4.71 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
-80.4 M | $ 1.45 | 5.84 % | $ 1.93 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
-200 M | $ 23.53 | 1.73 % | $ 654 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-4.94 B | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
1.39 B | $ 178.34 | 1.53 % | $ 8.84 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | USA |
 |
Interpace Biosciences
IDXG
|
-211 M | $ 2.2 | -4.35 % | $ 9.73 M | USA |
 |
Danaher Corporation
DHR
|
46.9 B | $ 195.87 | 3.3 % | $ 140 B | USA |
 |
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.24 B | $ 126.96 | 4.99 % | $ 20.2 B | USA |
 |
Fulgent Genetics
FLGT
|
590 M | $ 15.3 | 6.03 % | $ 463 M | USA |
 |
Guardant Health
GH
|
-2.99 B | $ 82.21 | 4.59 % | $ 10.3 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.75 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
-252 M | $ 2.85 | 5.95 % | $ 92.5 K | USA |
 |
Medpace Holdings
MEDP
|
-460 M | $ 501.23 | 1.56 % | $ 14.5 B | USA |
 |
Biomerica
BMRA
|
-53.2 M | $ 2.08 | -2.8 % | $ 4.78 M | USA |
 |
ICON Public Limited Company
ICLR
|
2.72 B | $ 110.37 | 3.33 % | $ 9.1 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 264.18 | 1.25 % | $ 22 B | USA |
 |
Celcuity
CELC
|
-449 M | $ 120.4 | 2.78 % | $ 5.63 B | USA |
 |
Myriad Genetics
MYGN
|
-1.12 B | $ 4.59 | 5.52 % | $ 425 M | USA |
 |
NeoGenomics
NEO
|
-434 M | $ 8.0 | 4.03 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
-536 M | $ 9.14 | -2.97 % | $ 1.98 B | USA |
 |
Lantheus Holdings
LNTH
|
680 M | $ 81.67 | 1.34 % | $ 5.51 B | USA |
 |
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K | Israel |
 |
Natera
NTRA
|
-1.94 B | $ 201.9 | 4.6 % | $ 19.9 B | USA |
 |
Invitae Corporation
NVTA
|
-4.83 B | - | - | $ 21.2 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
9.99 B | $ 192.91 | 0.73 % | $ 21.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-110 M | $ 5.19 | 5.06 % | $ 4.08 M | USA |
 |
National Research Corporation
NRC
|
-17.3 M | $ 16.82 | 2.03 % | $ 376 M | USA |
 |
Organovo Holdings
ONVO
|
-342 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | USA |
 |
Pacific Biosciences of California
PACB
|
-2.7 B | $ 1.45 | 8.21 % | $ 435 M | USA |
 |
Psychemedics Corporation
PMD
|
-16.8 M | - | -1.84 % | $ 15.3 M | USA |